These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 719602)
21. Complete response of metastatic adrenal cortical carcinoma to o,p'-DDD in a child. Krzisnik C; Petric G; Jereb B Pediatr Hematol Oncol; 1988; 5(1):65-9. PubMed ID: 3152953 [No Abstract] [Full Text] [Related]
22. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009 [TBL] [Abstract][Full Text] [Related]
23. Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p'-DDD] and its p,p'- and m,p'-isomers. Cai W; Benitez R; Counsell RE; Djanegara T; Schteingart DE; Sinsheimer JE; Wotring LL Biochem Pharmacol; 1995 May; 49(10):1483-9. PubMed ID: 7763292 [TBL] [Abstract][Full Text] [Related]
24. o,p'-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis. Touitou Y; Moolenaar AJ; Bogdan A; Auzéby A; Luton JP Eur J Clin Pharmacol; 1985; 29(4):483-7. PubMed ID: 4092727 [TBL] [Abstract][Full Text] [Related]
25. Use of GC/MS/SIM for rapid determination of plasma levels of o,p'-DDD, o,p'-DDE and o,p'-DDA. Inouye M; Mio T; Sumino K Clin Chim Acta; 1987 Dec; 170(2-3):305-14. PubMed ID: 3436064 [TBL] [Abstract][Full Text] [Related]
27. [Metabolism of o,p'-DDD (mitotane) in human and animals. Actual notions and practical deductions (author's transl)]. Touitou Y; Bogdan A; Legrand JC; Desgrez P Ann Endocrinol (Paris); 1977; 38(1):13-25. PubMed ID: 324349 [TBL] [Abstract][Full Text] [Related]
28. Two-dimensional chromatography for enantiomeric analysis of mitotane and its metabolite o,p'-DDA in patients with adrenocortical carcinoma indicates enantioselective metabolism. Stadler G; de Almeida Veiga A; Rita Corso C; Bach de Assis C; de Toledo Nogueira B; Regina Rocha Martins L; Cruz Bonk B; Lada Degaut Pontes F; Cavalcante de Figueiredo B; Mera de Souza L Bioorg Chem; 2023 Dec; 141():106835. PubMed ID: 37713949 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of the adrenocorticolytic compounds 3-methylsulphonyl-DDE and o,p'-DDD (mitotane) in Minipigs. Hermansson V; Cantillana T; Hovander L; Bergman A; Ljungvall K; Magnusson U; Törneke K; Brandt I Cancer Chemother Pharmacol; 2008 Feb; 61(2):267-74. PubMed ID: 17431626 [TBL] [Abstract][Full Text] [Related]
30. Glucocorticoid and mineralocorticoid pathways in two adrenocortical carcinomas: comparison of the effects of o,p'-dichlorodiphenyldichloroethane, aminoglutethimide and 2-p-aminophenyl-2-phenylethylamine in vitro. Touitou Y; Bogdan A; Auzeby A; Dommergues JP J Endocrinol; 1979 Jul; 82(1):87-94. PubMed ID: 479738 [TBL] [Abstract][Full Text] [Related]
31. Contribution of Therapeutic Monitoring in the Assessment of Toxic Adverse Effects of Mitotane: a Case Report. Jebabli N; Gaïes E; Eljebari H; Charfi R; Lakhal M; Klouz A; Salouage I; Trabelsi S Therapie; 2015; 70(6):545-6. PubMed ID: 26242497 [TBL] [Abstract][Full Text] [Related]
32. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? Dickstein G; Shechner C; Arad E; Best LA; Nativ O J Clin Endocrinol Metab; 1998 Sep; 83(9):3100-3. PubMed ID: 9745410 [TBL] [Abstract][Full Text] [Related]
33. Mitotane effects in a H295R xenograft model of adjuvant treatment of adrenocortical cancer. Lindhe O; Skogseid B Horm Metab Res; 2010 Sep; 42(10):725-30. PubMed ID: 20665429 [TBL] [Abstract][Full Text] [Related]
34. Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o,p'-DDD in human adrenal zona fasciculata/reticularis. Lindhe O; Skogseid B; Brandt I J Clin Endocrinol Metab; 2002 Mar; 87(3):1319-26. PubMed ID: 11889204 [TBL] [Abstract][Full Text] [Related]
35. Effects of o,p'-DDE, a Mitotane Metabolite, in an Adrenocortical Carcinoma Cell Line. Bach C; Corso CR; Veiga AA; Paraizo MM; de Souza LM Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558937 [TBL] [Abstract][Full Text] [Related]
36. Comparative CYP-dependent binding of the adrenocortical toxicants 3-methylsulfonyl-DDE and o,p'-DDD in Y-1 adrenal cells. Hermansson V; Asp V; Bergman A; Bergström U; Brandt I Arch Toxicol; 2007 Nov; 81(11):793-801. PubMed ID: 17487473 [TBL] [Abstract][Full Text] [Related]
37. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. Hermsen IG; Fassnacht M; Terzolo M; Houterman S; den Hartigh J; Leboulleux S; Daffara F; Berruti A; Chadarevian R; Schlumberger M; Allolio B; Haak HR; Baudin E J Clin Endocrinol Metab; 2011 Jun; 96(6):1844-51. PubMed ID: 21470991 [TBL] [Abstract][Full Text] [Related]
38. Development and validation of a liquid chromatography coupled to a diode array detector (LC-DAD) method for measuring mitotane (DDD) in plasma samples. Marques ASF; Alves ANL; Mendonca BB; Lima-Valassi HP Clinics (Sao Paulo); 2024; 79():100470. PubMed ID: 39128398 [TBL] [Abstract][Full Text] [Related]
39. [The effects of o,p'-DDD on adrenal steroidogenesis and hepatic steroid metabolism]. Ojima M; Saitoh M; Itoh N; Kusano Y; Fukuchi S; Naganuma H Nihon Naibunpi Gakkai Zasshi; 1985 Mar; 61(3):168-78. PubMed ID: 3874792 [TBL] [Abstract][Full Text] [Related]
40. [Cancer of the adrenal cortex treated by O,P"-DDD (author's transl)]. Van Geertruyden J; De Myttenaere M; Corvilain J Acta Chir Belg; 1980; 79(4):299-302. PubMed ID: 7468032 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]